Central Nervous System Toxicity from Cancer Therapies

Hematology/Oncology Clinics of North America

Volumn 20, Issue 6, 2006, Pages 1377-1398

  Schiff, David ^a   Wen, Patrick ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ASPARAGINASE; BUSULFAN; CARBOPLATIN; CARBOXYPEPTIDASE G2; CARMUSTINE; CISPLATIN; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DOCETAXEL; DONEPEZIL; FLUDARABINE; FLUOROURACIL; FOLINIC ACID; IFOSFAMIDE; IMATINIB; INTERLEUKIN 2; LEVAMISOLE; LOMUSTINE; METHOTREXATE; METHYLPHENIDATE; OXALIPLATIN; PACLITAXEL; PENTOSTATIN; PROCARBAZINE; RETINOID; THALIDOMIDE; UNINDEXED DRUG; VINCRISTINE;

ACUTE BRAIN DISEASE; ACUTE LYMPHOCYTIC LEUKEMIA; ASEPTIC MENINGITIS; ATAXIA; BACKACHE; BLURRED VISION; BRAIN DISEASE; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN LYMPHOMA; BRAIN PSEUDOTUMOR; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; CARCINOMATOUS MENINGITIS; CENTRAL NERVOUS SYSTEM; CEREBELLAR ATAXIA; CEREBRAL BLINDNESS; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHRONIC PROGRESSIVE RADIATION MYELOPATHY; COGNITIVE DEFECT; COMA; CONFUSION; DELUSION; DEMENTIA; DEPRESSION; DIZZINESS; DRUG INDUCED HEADACHE; ENCEPHALITIS; EUPHORIA; FEVER; GLIOBLASTOMA; GLIOMA; HALLUCINATION; HEAD AND NECK TUMOR; HUMAN; HYPONATREMIA; INSOMNIA; KIDNEY CARCINOMA; LEG PAIN; LETHARGY; LEUKEMIA; LEUKEMIC MENINGITIS; LEUKOENCEPHALOPATHY; LUNG TUMOR; LYMPHOMA; MANIA; MELANOMA; MENINGEAL METASTASIS; MENTAL DETERIORATION; MIGRAINE; MULTIPLE MYELOMA; NAUSEA; NEUROTOXICITY; OPTIC NERVE DISEASE; OVARY TUMOR; PARAPLEGIA; PARKINSONISM; PRIORITY JOURNAL; RADIATION INJURY; RADIATION NECROSIS; REVIEW; SARCOMA; SEIZURE; SIDE EFFECT; SOMNOLENCE; SPINAL CORD DISEASE; SPINAL CORD HEMORRHAGE; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREMOR; VASCULAR DISEASE; VOMITING;

ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM; HUMANS; NEUROTOXICITY SYNDROMES; RADIOTHERAPY;

EID: 33751108759     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2006.09.004     Document Type: Review

References (66)

1. Posner J.B. Neurologic complications of cancer (1995), F.A. Davis Company, Philadelphia
2. Schiff D., and Wen P.Y. Cancer neurology in clinical practice (2002), Humana Press, Totowa (NJ)
3. In: Schiff D., and O'Neill B.P. (Eds). Principles of neuro-oncology (2005), McGraw-Hill, New York
4. In: Rottenberg D.A. (Ed). Neurological complications of cancer treatment (1991), Butterworth-Heinemann, Stoneham (MA)
5. Behin A., and Delattre J.Y. Neurologic sequelae of radiotherapy on the nervous system. In: Schiff D., and Wen P.Y. (Eds). Cancer neurology in clinical practice (2002), Humana Press, Totowa (NJ) 173-191
6. Monje M.L., and Palmer T. Radiation injury and neurogenesis. Curr Opin Neurol 16 2 (2003) 129-134
7. Madsen T.M., Kristjansen P.E., Bolwig T.G., et al. Arrested neuronal proliferation and impaired hippocampal function following fractionated brain irradiation in the adult rat. Neuroscience 119 3 (2003) 635-642
8. van Vulpen M., Kal H.B., Taphoorn M.J., et al. Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy?. [review]. Oncol Rep 9 4 (2002) 683-688
9. de Wit M.C., de Bruin H.G., Eijkenboom W., et al. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 63 3 (2004) 535-537
10. Vigliani M.C., Sichez N., Poisson M., et al. A prospective study of cognitive functions following conventional radiotherapy for supratentorial gliomas in young adults: 4-year results. Int J Radiat Oncol Biol Phys 35 3 (1996) 527-533
11. Armstrong C.L., Hunter J.V., Ledakis G.E., et al. Late cognitive and radiographic changes related to radiotherapy: initial prospective findings. Neurology 59 1 (2002) 40-48
12. Creange A., Felten D., Kiesel I., et al. Leucoencéphalopathie subaiguë du rhombencéphale après radiotherapie hypophysaire [Subacute leukoencephalopathy of the rhombencephalon after pituitary radiotherapy]. Rev Neurol (Paris) 150 10 (1994) 704-708 [in French]
13. Schlienger M., Atlan D., Lefkopoulos D., et al. Linac radiosurgery for cerebral arteriovenous malformations: results in 169 patients. Int J Radiat Oncol Biol Phys 46 5 (2000) 1135-1142
14. Oppenheimer J.H., Levy M.L., Sinha U., et al. Radionecrosis secondary to interstitial brachytherapy: correlation of magnetic resonance imaging and histopathology. Neurosurgery 31 2 (1992) 336-343
15. Rock J.P., Scarpace L., Hearshen D., et al. Associations among magnetic resonance spectroscopy, apparent diffusion coefficients, and image-guided histopathology with special attention to radiation necrosis. Neurosurgery 54 5 (2004) 1111-1117 [discussion 1117-9]
16. Glantz M.J., Burger P.C., Friedman A.H., et al. Treatment of radiation-induced nervous system injury with heparin and warfarin. Neurology 44 11 (1994) 2020 [see comments]
17. Chuba P.J., Aronin P., Bhambhani K., et al. Hyperbaric oxygen therapy for radiation-induced brain injury in children. Cancer 80 10 (1997) 2005-2012
18. DeAngelis L.M., Delattre J.Y., and Posner J.B. Radiation-induced dementia in patients cured of brain metastases. Neurology 39 6 (1989) 789
19. Meyers C.A., Weitzner M.A., Valentine A.D., et al. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol 16 7 (1998) 2522-2527
20. Weitzner M.A., Meyers C.A., and Valentine A.D. Methylphenidate in the treatment of neurobehavioral slowing associated with cancer and cancer treatment. J Neuropsychiatry Clin Neurosci 7 3 (1995) 347-350
21. Rapp S.R., D'Agostini R.B., Lovato J., et al. Improving cognitive functioning in brain irradiated patients: a phase II trial of an acetylcholinesterase inhibitor. Neuro-oncol 6 4 (2004) 358
22. Crossen J.R., Garwood D., Glatstein E., et al. Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol 12 3 (1994) 627-642
23. Thiessen B., and DeAngelis L.M. Hydrocephalus in radiation leukoencephalopathy: results of ventriculoperitoneal shunting. Arch Neurol 55 5 (1998) 705-710
24. Salvati M., Frati A., Russo N., et al. Radiation-induced gliomas: report of 10 cases and review of the literature. Surg Neurol 60 1 (2003) 60-67 [discussion 67]
25. Loeffler J.S., Niemierko A., and Chapman P.H. Second tumors after radiosurgery: tip of the iceberg or a bump in the road?. Neurosurgery 52 6 (2003) 1436-1440 [discussion 1440-32]
26. Schiff D., Shin D.M., Moots P.L., et al. Neurologic complications of head and neck cancer. In: Schiff D., and Wen P.Y. (Eds). Cancer neurology in clinical practice (2003), Humana Press, Totowa (NJ) 425-434
27. Fouladi M., Langston J., Mulhern R., et al. Silent lacunar lesions detected by magnetic resonance imaging of children with brain tumors: a late sequela of therapy. J Clin Oncol 18 4 (2000) 824-831
28. Alfonso E.R., De Gregorio M.A., Mateo P., et al. Radiation myelopathy in over-irradiated patients: MR imaging findings. Eur Radiol 7 3 (1997) 400-404
29. Calabro F., and Jinkins J.R. MRI of radiation myelitis: a report of a case treated with hyperbaric oxygen. Eur Radiol 10 7 (2000) 1079-1084
30. Wen P.Y. Central nervous system complications of cancer therapy. In: Schiff D., and Wen P.Y. (Eds). Cancer neurology in clinical practice (2003), Humana Press, Totowa (NJ) 215-231
31. Grewal AK, Matsumoto JA, Waldron P, et al. Focal neurological dysfunction secondary to methotrexate neurotoxicity: correlation with magnetic resonance imaging. Presented at the American Academy of Neurology 56th Annual Meeting. San Francisco, April 24-May 1, 2004.
32. Yim Y.S., Mahoney Jr. D.H., and Oshman D.G. Hemiparesis and ischemic changes of the white matter after intrathecal therapy for children with acute lymphocytic leukemia. Cancer 67 8 (1991) 2058-2061
33. Widemann B.C., Balis F.M., Shalabi A., et al. Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2. J Natl Cancer Inst 96 20 (2004) 1557-1559
34. Martino R.L., Benson III A.B., Merritt J.A., et al. Transient neurologic dysfunction following moderate-dose methotrexate for undifferentiated lymphoma. Cancer 54 9 (1984) 2003-2005
35. Walker R.W., Allen J.C., Rosen G., et al. Transient cerebral dysfunction secondary to high-dose methotrexate. J Clin Oncol 4 12 (1986) 1845-1850
36. Sanchez-Carpintero R., Narbona J., Lopez de Mesa R., et al. Transient posterior encephalopathy induced by chemotherapy in children. Pediatr Neurol 24 2 (2001) 145-148
37. Pizzo P.A., Poplack D.G., and Bleyer W.A. Neurotoxicities of current leukemia therapy. Am J Pediatr Hematol Oncol 1 2 (1979) 127-140
38. Ochs J., Mulhern R., Fairclough D., et al. Comparison of neuropsychologic functioning and clinical indicators of neurotoxicity in long-term survivors of childhood leukemia given cranial radiation or parenteral methotrexate: a prospective study. J Clin Oncol 9 1 (1991) 145-151
39. Guha-Thakurta N., Damek D., Pollack C., et al. Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients. J Neurooncol 43 3 (1999) 259-268
40. Neuwelt E.A., Guastadisegni P.E., Varallyay P., et al. Imaging changes and cognitive outcome in primary CNS lymphoma after enhanced chemotherapy delivery. AJNR Am J Neuroradiol 26 2 (2005) 258-265
41. Fliessbach K., Helmstaedter C., Urbach H., et al. Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study. Neurology 64 7 (2005) 1184-1188
42. Correa D.D., DeAngelis L.M., Shi W., et al. Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 62 4 (2004) 548-555
43. Zalupski M., and Baker L.H. Ifosfamide. J Natl Cancer Inst 80 8 (1988) 556-566
44. Meanwell C.A., Blake A.E., Kelly K.A., et al. Prediction of ifosfamide/mesna associated encephalopathy. Eur J Cancer Clin Oncol 22 7 (1986) 815-819
45. Van Dyk J.J., Falkson H.C., Van der Merwe A.M., et al. Unexpected toxicity in patients treated with iphosphamide. Cancer Res 32 5 (1972) 921-924
46. Curtin J.P., Koonings P.P., Gutierrez M., et al. Ifosfamide-induced neurotoxicity. Gynecol Oncol 42 3 (1991) 193-196 [discussion 191-2]
47. Chastagner P., Sommelet-Olive D., Kalifa C., et al. Phase II study of ifosfamide in childhood brain tumors: a report by the French Society of Pediatric Oncology (SFOP). Med Pediatr Oncol 21 1 (1993) 49-53
48. Kumar S., Witzig T.E., and Rajkumar S.V. Thalidomid: current role in the treatment of non-plasma cell malignancies. J Clin Oncol 22 12 (2004) 2477-2488
49. Cavaletti G., Beronio A., Reni L., et al. Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study. Neurology 62 12 (2004) 2291-2293
50. Herzig R.H., Herzig G.P., Wolff S.N., et al. Central nervous system effects of high-dose cytosine arabinoside. Semin Oncol 14 2, Suppl 1 (1987) 21-24
51. Herzig R.H., Hines J.D., Herzig G.P., et al. Cerebellar toxicity with high-dose cytosine arabinoside. J Clin Oncol 5 6 (1987) 927-932
52. Winkelman M.D., and Hines J.D. Cerebellar degeneration caused by high-dose cytosine arabinoside: a clinicopathological study. Ann Neurol 14 5 (1983) 520-527
53. Kieslich M., Porto L., Lanfermann H., et al. Cerebrovascular complications of L-asparaginase in the therapy of acute lymphoblastic leukemia. J Pediatr Hematol Oncol 25 6 (2003) 484-487
54. Patten S.B., and Neutel C.I. Corticosteroid-induced adverse psychiatric effects: incidence, diagnosis and management. Drug Saf 22 2 (2000) 111-122
55. Rundell J.R., and Wise M.G. Causes of organic mood disorder. J Neuropsychiatry Clin Neurosci 1 4 (1989) 398-400
56. Cronk M., Abraham R., and Perrin L. Case report of a generalized seizure related to paclitaxel infusion. J Natl Cancer Inst 96 6 (2004) 487
57. Ziske C.G., Schottker B., Gorschluter M., et al. Acute transient encephalopathy after paclitaxel infusion: report of three cases. Ann Oncol 13 4 (2002) 629-631
58. Nieto Y., Cagnoni P.J., Bearman S.I., et al. Acute encephalopathy: a new toxicity associated with high-dose paclitaxel. Clin Cancer Res 5 3 (1999) 501-506
59. Hensley M.L., Peterson B., Silver R.T., et al. Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013. J Clin Oncol 18 6 (2000) 1301-1308
60. Ulbricht D., Metz R.J., Ries F., et al. [Alpha]-interferon encephalopathy. Neurology 61 9 (2003) 1301
61. Amodio P., De Toni E.N., Cavalletto L., et al. Mood, cognition and EEG changes during interferon alpha (alpha-IFN) treatment for chronic hepatitis C. J Affect Disord 84 1 (2005) 93-98
62. Karp B.I., Yang J.C., Khorsand M., et al. Multiple cerebral lesions complicating therapy with interleukin-2. Neurology 47 2 (1996) 417
63. Somers S.S., Reynolds J.V., and Guillou P.J. Multifocal neurotoxicity during interleukin-2 therapy for malignant melanoma. Clin Oncol (R Coll Radiol) 4 2 (1992) 135-136
64. Saris S.C., Patronas N.J., Rosenberg S.A., et al. The effect of intravenous interleukin-2 on brain water content. J Neurosurg 71 2 (1989) 169-174
65. Subach B.R., Witham T.F., Kondziolka D., et al. Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series. Neurosurgery 45 1 (1999) 17-22 [discussion 22-3]
66. McGovern P.C., Lautenbach E., Brennan P.J., et al. Risk factors for postcraniotomy surgical site infection after 1,3-bis (2-chloroethyl)-1-nitrosourea (Gliadel) wafer placement. Clin Infect Dis 36 6 (2003) 759-765